AbbVie Inc. (NYSE:ABBV) is considered one of the best stocks for the next decade, with price target upgrades from Morgan Stanley and HSBC in December 2025. Analysts downplay competitive threat from J&J’s Tremfya, citing AbbVie’s strong growth momentum and operational execution.

In Q3 2025, AbbVie reported total net revenues of ~$15.8 billion, up 9.10% YoY. Skyrizi and Rinvoq drove growth in the immunology segment, offsetting Humira’s decline. Oncology sector remained stable. AbbVie continues to dominate in immunology treatments, earning $1.86 per share, beating estimates by $0.08.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company focusing on research, development, manufacture, and sale of medicines globally. The company continues to innovate in the field of immunology and neuroscience, driving revenue growth and market dominance.

While ABBV presents investment potential, some AI stocks offer greater upside with lower downside risk. Consider exploring undervalued AI stocks for significant benefits from current market trends. For more insights on potential AI investments, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share